Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
Third Quarter 2020 XPOVIO Net Product Sales of $21.3 Million; Quarterly Sales Continue Strong Momentum, Increasing Approximately 15% Compared to the Second Quarter of 2020
XPOVIO Supplemental New Drug Application Seeking Approval for Patients with Multiple Myeloma After At Least One Prior Line of Therapy Assigned a Target PDUFA Action Date of March 19, 2021
Conference Call Scheduled for Today at 4:30 p.m. ET
See press releases HERE.
See our KPTI AmpCards HERE.